Exclusive Summary

• • Off-patent with a standard 0.5 mg strength; Asia is the main Rx market allowing rapid registration and scaling.
• • Large addressable population: 160–270 million with diabetic peripheral neuropathy plus 5–20% B12 deficiency prevalence drive steady demand.
• • Clinical role as B12 correction and neurotrophic adjunct fits real-world practice and combines well with first-line DPN analgesics.
• • JP-pharmacopeia API and Tech Transfer enable entry into Japan/ASEAN markets and support government tenders via local manufacturing.
• • Generics typically 60–90% cheaper than originator/brand leaders; sub-$0.10 per tablet feasible in many markets for high-volume distribution.